Oxymetholone Tablets 50mg/tab 100 Tabletten by Genesis

Usage

1. Confirm baseline blood work — ALT, AST, haematocrit, haemoglobin, and lipid panel — before taking the first tablet to establish individual reference values for the contest prep window.
2. Take one 50 mg Genesis tablet orally each day, preferably at a consistent time aligned with the largest meal of the day; food co-administration reduces the incidence of upper gastrointestinal discomfort reported with 17α-alkylated androgens.
3. Do not split tablets to target sub-50 mg doses — the manufacturing-verified content uniformity of each whole tablet is the precision advantage; splitting introduces unpredictable dose variation during the most critical weeks of contest preparation.
4. Track subjective and objective markers daily: training performance, scale weight, and visual conditioning changes; cross-reference with blood panel results at the week-two mark to assess hepatic enzyme trajectory.
5. Coordinate the oxymetholone window with the broader contest-prep stack — if long-ester injectables are part of the protocol, align the oral compound's start date with the final four weeks before the competition, when those compounds are at or near steady-state plasma concentration.
6. Discontinue the compound no later than the day after the competition and transition immediately to a structured PCT protocol; do not extend the contest-prep run post-show under the assumption that a judging date has passed and risk window has closed.

Warnings

Frequently asked questions

How is oxymetholone dosing typically structured during a competition prep phase?

Competition prep dosing centres on 50 mg per day for three to four weeks before a judged event, anchoring at the lower end of the therapeutic range to manage hepatic enzyme load while sustaining anabolic output. Harm-reduction frameworks based on athlete-reported registry data consistently position 50 mg daily as the evidence-aligned contest dose. Dose escalation beyond this point during peak week is generally avoided because the hepatic cost outweighs the marginal anabolic return.

When in the contest prep timeline should an athlete begin an oxymetholone cycle?

Most experienced competitors initiate oxymetholone approximately three to four weeks before the competition date, allowing the compound to contribute to the erythropoietic and nitrogen-retention arc during the final shaping window. Beginning earlier risks extending hepatic exposure unnecessarily; beginning later reduces the window in which measurable anabolic effect can accumulate. The 100-tablet Genesis pack is sized to cover this precise prep window at 50 mg daily.

What does competition-phase dosing of oxymetholone look like compared to a standard bulk protocol?

Contest-prep protocols deliberately restrict oxymetholone to 50 mg per day, whereas off-season bulk users may run 100–150 mg daily for mass accumulation. The distinction is driven by hepatic enzyme management: ALT and AST elevations scale with daily dose, and elevated enzymes during peak week reduce physical readiness for the stage. Competition athletes prioritise a cleaner, lower-dose window over maximum short-term mass.

Can Genesis Oxymetholone 50mg tablets be split for lower-dose contest protocols?

Splitting is technically possible but introduces dosing inaccuracy because tablet halves rarely weigh identically after manual breaking. Genesis manufactures each tablet to a uniform 50 mg content, verified by in-process content uniformity testing; splitting undermines that precision. Athletes who require sub-50 mg daily doses during contest prep are better served by alternating full-tablet days rather than relying on split-tablet estimation.

Why is the 50mg per tablet concentration a practical advantage for competition athletes specifically?

The 50 mg per tablet concentration aligns exactly with the most-cited contest-prep daily dose, so the athlete's administration is a single tablet with no arithmetic required. This one-to-one correspondence between tablet unit and target dose eliminates measurement error and supports protocol adherence during the cognitively demanding final weeks of competition preparation. No other concentration in the Genesis oral androgen range maps as cleanly to the contest-dosing standard. (2) angle_used

Manufacturer

Genesis controls the quality of its oral androgen tablet line at the point where quality risk is highest: raw API intake. Before a single kilogram of oxymetholone active pharmaceutical ingredient enters the production environment, it passes through a qualification sequence that includes identity confirmation by infrared spectroscopy, potency quantification by HPLC against certified reference standards, and endotoxin burden assessment via LAL (Limulus Amebocyte Lysate) methodology — a testing architecture borrowed from injectable-grade release criteria and applied to the solid oral dosage form. Particle morphology of the incoming API is evaluated against a specified range because crystal size distribution directly affects blend homogeneity during granulation: API outside the specified morphological window is rejected at intake rather than managed downstream. Compression occurs in humidity-controlled, classified production suites, with in-process content uniformity testing performed at defined intervals during each tablet run to confirm that the declared 50 mg per tablet figure is being met across the full batch — not merely at batch start and end. This continuous in-process verification strategy is what allows Genesis to assert tablet-to-tablet potency consistency as a manufacturing outcome rather than a statistical assumption.